Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

Silexion uses September conferences to showcase its KRAS-focused pipeline and hold investor meetings while advancing SIL204 in Phase 2/3 trials.

Rhea-AI Summary

Silexion Therapeutics (SLXN) will participate in three industry and investor conferences in September 2026 to present its oncology programs and meet investors.

The company will present at the Oncology & Immunology Innovation Partnering & Licensing Summit on September 9, 2026 and the 8th Annual RAS-Targeted Drug Development Summit on September 10, 2026, both in Boston, led by Chief Scientific and Development Officer Dr. Mitchell Shirvan. From September 14–16, 2026, Silexion will hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference in New York with its CEO and CFO attending.

Silexion is developing SIL204, an investigational pan-KRAS RNA interference therapy in an ongoing Phase 2/3 program for locally advanced pancreatic cancer.

Key Terms

rna interference, phase 2/3, small interfering rna

3 terms

rna interference technical

"pioneering RNA interference (RNAi) therapies for KRAS-driven cancers"

RNA interference is a natural cellular process that acts like a mute switch to reduce or silence the activity of a specific gene by targeting its messenger RNA, the blueprint used to make a protein. For investors, it matters because therapies and diagnostics that harness this mechanism can precisely block disease-causing proteins, creating new drug classes with high potential reward but also scientific, manufacturing and regulatory risks that affect company value.

phase 2/3 medical

"an ongoing Phase 2/3 clinical program in locally advanced pancreatic cancer"

A phase 2/3 trial is a combined clinical study that first evaluates how well a treatment works and the best dose, then expands into a larger test to confirm those results and safety. For investors, it matters because moving into a phase 2/3 signals that an experimental therapy has shown initial promise and will be tested at scale, which can materially change the odds and timeline for regulatory approval and commercial potential.

small interfering rna technical

"a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation"

Small interfering RNA (siRNA) are short, lab-made strands of genetic material that act like a mute button inside cells, binding to a specific genetic message and preventing a particular protein from being made. For investors, siRNA represents a drug technology with the potential to treat diseases by precisely turning off harmful genes, which can mean high development costs, regulatory hurdles, intellectual property value, and the possibility of breakthrough therapies that change market dynamics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Grand Cayman, Cayman Islands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that members of its management team will participate in the following industry and investor conferences in September 2026:

Oncology & Immunology Innovation Partnering & Licensing Summit
Presentation date: September 9, 2026
Location: Hotel Commonwealth, Boston, MA
Format: Presentation
Presenter: Dr. Mitchell Shirvan, Chief Scientific and Development Officer

8th Annual RAS-Targeted Drug Development Summit
Presentation date: September 10, 2026
Location: The Colonnade Hotel, Boston, MA
Format: Presentation
Presenter: Dr. Mitchell Shirvan, Chief Scientific and Development Officer

H.C. Wainwright 28th Annual Global Investment Conference
Dates: September 14–16, 2026
Location: Lotte New York Palace Hotel, New York, NY
Format: One-on-one meetings
Attendees: Ilan Hadar, Chief Executive Officer; Mirit Horenshtein Hadar, Chief Financial Officer

Parties interested in meeting with Silexion’s management during the conferences should contact their conference representative or the Company’s Investor Relations team to arrange a meeting.

Silexion is currently developing SIL204, an investigational pan-KRAS RNA interference therapy, in an ongoing Phase 2/3 clinical program in locally advanced pancreatic cancer.

About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation in Israel and the European Union in locally advanced pancreatic cancer. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the Company’s planned participation, presentations, and meetings at industry and investor conferences; the development of SIL204 and the conduct of its ongoing Phase 2/3 clinical program in locally advanced pancreatic cancer; and the potential therapeutic benefits and clinical utility of SIL204, are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the degree of success of Silexion’s ongoing and planned clinical trials, including the Phase 2/3 clinical trial of SIL204; (ii) whether Silexion is able to successfully execute upon its strategy and plans via its future operations, and maintain a positive financial position; (iii) the impact of the regulatory environment and compliance complexities; (iv) whether Silexion is able to develop future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and sources and uses of cash, and the potential impact on the Company’s operations of any inability to secure such capital; (vi) the substantial doubt about the Company’s ability to continue as a going concern described in Note 1(g) to the Company’s unaudited condensed consolidated financial statements for the three-month and six-month periods ended June 30, 2026; (vii) whether Silexion succeeds at maintaining its Nasdaq listing; and (viii) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026, and subsequent filings with the SEC. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com

FAQ

How can interested parties arrange meetings with Silexion at these September 2026 conferences?

Parties interested in meeting with Silexion’s management during the conferences are instructed to contact their conference representative or the Company’s Investor Relations team to arrange a meeting.

What is Silexion’s lead clinical program mentioned in the announcement?

Silexion is advancing SIL204, a small interfering RNA (siRNA) pan-KRAS RNA interference therapy, in an ongoing Phase 2/3 clinical program for locally advanced pancreatic cancer in Israel and the European Union.

What prior clinical experience does Silexion have with KRAS-targeted therapies?

The company conducted a Phase 2a clinical trial with its first-generation product candidate, which showed a positive trend compared with chemotherapy alone, and is now focusing on its second-generation candidate, SIL204.